Beta-blockers are considered as suitable drugs to treat essential hypertension also in elderly patients and they
are currently recommended for treatment of hypertension, even in older patients, by the ESH/ESC Guidelines. Different
meta-analyses and results of some large clinical trials have shown that here is no clinically difference between β-blockers
and other drug classes in decreasing high blood pressure in elderly hypertensive patients. The new vasodilating
β-blockers, as nebivolol, carvedilol and celiprolol, offer additional important advantages, compared with traditional
β-blockers. The cardio-protective effect of β-blockers (except atenolol) is not inferior to that obtained with other drug
classes which is independent of age and gender of the patients.